Paolocci Nazareno, Katori Tatsuo, Champion Hunter C, St John Marcus E, Miranda Katrina M, Fukuto Jon M, Wink David A, Kass David A
Division of Cardiology, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5537-42. doi: 10.1073/pnas.0937302100. Epub 2003 Apr 18.
Nitroxyl anion (HNONO(-)), the one-electron reduced form of nitric oxide (NO), induces positive cardiac inotropy and selective venodilation in the normal in vivo circulation. Here we tested whether HNO/NO(-) augments systolic and diastolic function of failing hearts, and whether contrary to NO/nitrates such modulation enhances rather than blunts beta-adrenergic stimulation and is accompanied by increased plasma calcitonin gene-related peptide (CGRP). HNO/NO(-) generated by Angelis' salt (AS) was infused (10 microg/kg per min, i.v.) to conscious dogs with cardiac failure induced by chronic tachycardia pacing. AS nearly doubled contractility, enhanced relaxation, and lowered cardiac preload and afterload (all P < 0.001) without altering plasma cGMP. This contrasted to modest systolic depression induced by an NO donor diethylamine(DEA)NO or nitroglycerin (NTG). Cardiotropic changes from AS were similar in failing hearts as in controls despite depressed beta-adrenergic and calcium signaling in the former. Inotropic effects of AS were additive to dobutamine, whereas DEA/NO blunted beta-stimulation and NTG was neutral. Administration of propranolol to nonfailing hearts fully blocked isoproterenol stimulation but had minimal effect on AS inotropy and enhanced lusitropy. Arterial plasma CGRP rose 3-fold with AS but was unaltered by DEA/NO or NTG, supporting a proposed role of this peptide to HNO/NO(-) cardiotropic action. Thus, HNO/NO(-) has positive inotropic and lusitropic action, which unlike NO/nitrates is independent and additive to beta-adrenergic stimulation and stimulates CGRP release. This suggests potential of HNO/NO(-) donors for the treatment of heart failure.
硝酰阴离子(HNONO(-))是一氧化氮(NO)的单电子还原形式,在正常体内循环中可诱导正性心肌收缩力和选择性静脉舒张。在此,我们测试了HNO/NO(-)是否能增强衰竭心脏的收缩和舒张功能,以及与NO/硝酸盐相反,这种调节是否能增强而非减弱β-肾上腺素能刺激,并伴有血浆降钙素基因相关肽(CGRP)增加。将由安吉利斯盐(AS)产生的HNO/NO(-)以10微克/千克每分钟的速度静脉内注入由慢性心动过速起搏诱导心力衰竭的清醒犬。AS使收缩力几乎加倍,增强了舒张,并降低了心脏前负荷和后负荷(所有P<0.001),而不改变血浆cGMP。这与NO供体二乙胺(DEA)NO或硝酸甘油(NTG)引起的适度收缩压降低形成对比。尽管衰竭心脏中的β-肾上腺素能和钙信号传导受到抑制,但AS引起的心脏效应在衰竭心脏和对照中相似。AS的正性肌力作用与多巴酚丁胺相加,而DEA/NO减弱β刺激,NTG则无作用。对非衰竭心脏给予普萘洛尔可完全阻断异丙肾上腺素刺激,但对AS的正性肌力作用影响最小,并增强了舒张性。动脉血浆CGRP随AS升高3倍,但不受DEA/NO或NTG影响,支持该肽在HNO/NO(-)心脏作用中的作用。因此,HNO/NO(-)具有正性肌力和舒张性作用,与NO/硝酸盐不同,它独立于β-肾上腺素能刺激并与之相加,并刺激CGRP释放。这表明HNO/NO(-)供体在治疗心力衰竭方面具有潜力。